Verrica Pharmaceuticals (VRCA) Preferred Stock Liabilities (2017)

Verrica Pharmaceuticals (VRCA) posted quarterly Preferred Stock Liabilities of $15.5 million for Q4 2017.

Verrica Pharmaceuticals (VRCA) Preferred Stock Liabilities (2017) Analysis & Trends

Verrica Pharmaceuticals' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $15.5 million for Q4 2017.

In Q4 2017, Preferred Stock Liabilities changed N/A year-over-year to $15.5 million; the TTM figure through Dec 2017 stood at $15.5 million (changed N/A YoY), while the FY2017 annual figure was $15.5 million, changed N/A from the prior year.
Preferred Stock Liabilities for Q4 2017 stood at $15.5 million.
The five-year high for Preferred Stock Liabilities was $15.5 million in Q4 2017, with the low at $15.5 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Verrica Pharmaceuticals	102.80 Mn	91.60 Mn	-	-

Download Data

Date	Value
Dec 31, 2017	15.51 Mn